Awarded Phase II SBIR Grant Lentigen for the clinical development of targeted immunotherapy for melanoma TCR

The ultimate goal of this program is to develop a new immunotherapy for melanoma invented by Dr. Nishimura. In particular, the collaboration will evaluate whether the clinical use of lentiviral vector-engineered T cells that express a high affinity receptor of T cells capable of recognizing melanoma / melanocyte tumor antigen, resulting in greater efficiency.NOTES It is said to offer many advantages for the patient, less time in hospital and a quicker recovery. It also has the potential to achieve better safe oncological laparoscopic surgery because it leaves no surgical scars, while laparoscopic surgery requires four or five small incisions.

Lentigen Corporation, a biotechnology company specializing in lentiviral gene delivery of development and production technologies, today announced it has received a National Institutes of Health Small Business Innovation Research grant program for the vector targeted clinical immunotherapy TCR melanoma. In this program, Lentigen will work with Dr. Michael Nishimura, Professor of Surgery at the Medical University of South Carolina .

While the adoptive transfer of T cells in melanoma patients may lead to the clinical objective responses in approximately 50 percent of patients, it is often difficult to obtain tumor-reactive T cells from all patients. Our approach to genetically modify T cells for expressing anti-melanoma T-cell antigen receptors provides a potentially attractive solution to this problem, said Boro Dropulić, Lentigen President and Chief Scientific Officer. SBIR Phase II NIH grant will allow us to test this therapeutic approach for Phase I MUSC clinical trial.